NCT02257541View on ClinicalTrials.gov

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 2, 2014

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions
DRUG

BGJ398

DRUG

Imatinib Mesylate

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

77030

Md Anderson Cancer Center, Houston

02115

Dana Farber Cancer Institute, Boston

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

University of Pittsburgh

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02257541 - BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | Biotech Hunter | Biotech Hunter